US2016095883A1PendingUtilityA1

Method for the treatment of obesity

51
Assignee: DEPT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARYPriority: Jul 23, 2010Filed: Sep 28, 2015Published: Apr 7, 2016
Est. expiryJul 23, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Stanley R. RiddellMichael HudecekChristoph Rader
A61K 40/4202A61K 40/31A61K 40/11C07K 16/28C07K 2317/31C07K 2317/622A61K 2039/505A61K 39/3955C07K 2317/55A61K 35/17C12N 2740/15043C07K 2319/00C07K 16/2803C07K 14/72C07K 14/71C07K 2319/03C07K 14/7051C12N 15/85
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition, comprising primate cytolytic T lymphocytes modified to express a target-specific chimeric antigen receptor, wherein the target is a cell surface antigen preferentially expressed on an adipocyte. 
     
     
         2 . The composition of  claim 1 , wherein modified T lymphocytes are from endogenous T lymphocytes of the primate. 
     
     
         3 . The composition of  claims 1 , wherein the T lymphocytes are CD4+, CD8+, or a mixture thereof. 
     
     
         4 . The composition of  claim 1 , wherein the target is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) or AD3. 
     
     
         5 . The composition of  claim 1 , wherein the T lymphocytes are naïve cells, central memory cells, effector memory cells, or any combination thereof. 
     
     
         6 . The composition of  claim 5 , wherein the T lymphocytes are naïve cell having a phenotype of CD28+ CD62L+ CD95− and CD45RA+. 
     
     
         7 . The composition of  claim 5 , wherein the T lymphocytes are central memory cells having a phenotype of CD28+ CD62L+ CD95+ and CD45RA−. 
     
     
         8 . The composition of  claim 5 , wherein the T lymphocytes are effector memory cells having a phenotype of CD28−CD62L− and CD45RA−. 
     
     
         9 . The composition of  claim 1 , wherein the T lymphocytes are human. 
     
     
         10 . A method of eliminating adipocytes in an obese subject, comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to  claim 1 . 
     
     
         11 . The method of  claim 10 , further comprising administering a therapeutically effective amount of an immunotherapeutic antibody that specifically binds the target antigen preferentially expressed on the adipocyte. 
     
     
         12 . The method of  claim 10 , wherein the subject is human. 
     
     
         13 . A method of treating a condition associated with an obese subject, comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to  claim 1 . 
     
     
         14 . A kit, comprising a container containing a nucleic acid molecule encoding a target-specific chimeric antigen receptor, wherein the target is a cell surface antigen preferentially expressed on an adipocyte; and instructions for modifying an isolated T lymphocyte subpopulation by transducing with the nucleic acid molecule encoding the target-specific chimeric antigen receptor. 
     
     
         15 . The kit of  claim 14 , further comprising reagents for separation of T lymphocytes into naïve, central memory, and effector memory T lymphocyte subpopulations, wherein the reagents comprise antibodies directed to T lymphocyte surface antigens. 
     
     
         16 . The kit of  claim 15 , comprising an antibody specific for a T lymphocyte surface antigen selected from CD4, CD8, CD28, CD62L, CD95, CD45RA, or any combination thereof. 
     
     
         17 . The kit of  claim 14 , further comprising an antibody or fragment thereof specific for an antigen preferentially expressed on an adipocyte. 
     
     
         18 . The kit of  claim 17 , wherein the antibody or fragment thereof is specific for a receptor tyrosine kinase-like orphan receptor 1 (ROR1) or AD3. 
     
     
         19 . The kit of  claim 14 , further comprising an immunotherapeutic antibody or fragment thereof that specifically binds the target antigen preferentially expressed on the adipocyte. 
     
     
         20 . The kit of  claim 19 , wherein the immunotherapeutic antibody or fragment thereof is specific for a receptor tyrosine kinase-like orphan receptor 1 (ROR1) or AD3. 
     
     
         21 . The kit of  claim 20 , wherein the antibody is a monoclonal antibody, humanized antibody, or bispecific antibody. 
     
     
         22 . The kit according to  claim 20 , wherein the immunotherapeutic antibody fragment thereof comprises a single chain Fv (scFv), Fab, Fab′, Fab 2 , or Fab 2 ′. 
     
     
         23 . The kit according to  claim 20 , wherein the immunotherapeutic antibody or fragment thereof is conjugated to a cytotoxic molecule or radionuclide.

Join the waitlist — get patent alerts

Track US2016095883A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.